Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Mikołaj Woła̧cewicz, Rafał Hrynkiewicz, Ewelina Grywalska, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1181-1181
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

(Nano)platforms in bladder cancer therapy: Challenges and opportunities
Milad Ashrafizadeh, Ali Zarrabi, Hassan Karimi‐Maleh, et al.
Bioengineering & Translational Medicine (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 90
Nanotechnology in Bladder Cancer: Diagnosis and Treatment
Mahmood Barani, Seyedeh Maryam Hosseinikhah, Abbas Rahdar, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2214-2214
Open Access | Times Cited: 78
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro
Lei Yu, Zhichao Li, Hongbin Mei, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 2
Open Access | Times Cited: 63
Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy
Julieta Afonso, Céline S. Gonçalves, Marta Costa, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 982-982
Open Access | Times Cited: 22
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Sujit S. Nair, Rachel Weil, Zachary Dovey, et al.
Urologic Clinics of North America (2020) Vol. 47, Iss. 4, pp. e17-e54
Open Access | Times Cited: 65
Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
Cláudia Martins‐Lima, Ugo Chianese, Rosaria Benedetti, et al.
Frontiers in Molecular Biosciences (2023) Vol. 9
Open Access | Times Cited: 21
Identifying novel biomarkers associated with bladder cancer treatment outcomes
Peris Castaneda, Dan Theodorescu, Charles J. Rosser, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 20
Bladder Cancer and the Urinary Microbiome—New Insights and Future Directions: A Review
A Russo, Areeba Memon, Shahid Ahmed
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 2, pp. 434-444
Closed Access | Times Cited: 6
PLGA nanomedical consignation: A novel approach for the management of prostate cancer
Tenzin Sonam Dongsar, Tenzin Tsering Dongsar, Garima Gupta, et al.
International Journal of Pharmaceutics (2024) Vol. 652, pp. 123808-123808
Closed Access | Times Cited: 6
Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer
Fan-Xin Song, Xiaojian Xu, Hengze Ding, et al.
Biosensors (2023) Vol. 13, Iss. 1, pp. 106-106
Open Access | Times Cited: 14
The roles of FGFR3 and c-MYC in urothelial bladder cancer
Dereje E. Bogale
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Harnessing Aggregation‐Induced Emission‐Based Detection Toolbox for Diagnostics of Urogenital Tumors
Wenzhe Chen, Hantian Guan, Yongfeng Lu, et al.
Aggregate (2025)
Open Access
Review of recent molecular pathology of bladder urothelial carcinoma
Peng Su, Ying Yang, Hong Zheng
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Development and validation of a molecular prognostic index of bladder cancer based on immunogenomic landscape analysis
Ning Xu, Zhi‐Bin Ke, Xiao‐Dan Lin, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
Xingyu Chen, Haotian Chen, Dong He, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 32
A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration
Jiaochen Luan, Tengyue Zeng, Qijie Zhang, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 28
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca Wynn, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 19
Tumor Microenvironment in Urothelial Carcinoma: Focus on Metastatic Disease
Federica Cosso, M. Catalano, Giandomenico Roviello, et al.
(2025), pp. 1-30
Closed Access
Proteomic and In Silico Analyses Highlight Complement System’s Role in Bladder Cancer Immune Regulation
Tuğcan Korak, İbrahim Halil Baloğlu, Murat Kasap, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 735-735
Open Access
Biomarker-informed care for patients with renal cell carcinoma
M. Mckinnon, Brian I. Rini, Scott M. Haake
Nature Cancer (2025)
Closed Access
A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes
Qizhan Luo, Thomas‐Alexander Vögeli
Cancers (2020) Vol. 12, Iss. 10, pp. 3054-3054
Open Access | Times Cited: 32
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
Matthew D. Galsky, Arjun Vasant Balar, Peter C. Black, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002552-e002552
Open Access | Times Cited: 25
Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy
Ying Jiang, Xun Sun, Xiaoyun Song, et al.
Current Urology (2023) Vol. 17, Iss. 4, pp. 221-228
Open Access | Times Cited: 9
Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer
Zhouting Tuo, Yuan Lin, Ying Zhang, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
High expression of BTN3A1 is associated with clinical and immunological characteristics and predicts a poor prognosis in advanced human gliomas
Abdou-samad Kone, Amina Ghouzlani, Ahmed Qandouci, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top